Other studies suggested that endothelin receptor antagonists, such as HJ272, significantly reduced LPS-induced inflammatory reactions, such as neutrophils in BALF, expression of tumor necrosis factor receptor 1, alveolar septal cell apoptosis, and lung histopathological injury, suggesting a potential therapeutic target for neutrophil-driven lung diseases (60). This evidence concerns the gene TNFRSF1A and lung disorder.